<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03654573</url>
  </required_header>
  <id_info>
    <org_study_id>1801</org_study_id>
    <nct_id>NCT03654573</nct_id>
  </id_info>
  <brief_title>The MOCA I Study - Microvascular Obstruction With CoFI™ System Assessment</brief_title>
  <acronym>MOCA</acronym>
  <official_title>The MOCA I Study - Microvascular Obstruction With CoFI™ System Assessment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CorFlow Therapeutics AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CorFlow Therapeutics AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      First-in-Human study to assess the CoFI™ device related safety and the feasibility of the&#xD;
      diagnostic and the therapeutic sequence as well as the correlation between the dynamic&#xD;
      microvascular resistance (dMVR) and microvascular obstruction (MVO) as measured by MRI in&#xD;
      patients presenting with acute ST-elevation myocardial infarction (STEMI) undergoing&#xD;
      percutaneous coronary intervention (PCI).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2019</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>N= 50 Diagnostic and N= 20 Therapeutic</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of study device or study procedure adverse effect or event</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Safety Objective is the incidence of study device or study procedure adverse effect or event at up to 30 days. To assess the CoFI™ device related safety and the feasibility of the diagnostic and the therapeutic sequence as well as the correlation between the dynamic microvascular resistance (dMVR) and microvascular obstruction (MVO) as measured by MRI in patients presenting with acute ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic Success</measure>
    <time_frame>0 days</time_frame>
    <description>Ability to perform a diagnostic sequence and to calculate a base flow resistance curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic Success</measure>
    <time_frame>0 days</time_frame>
    <description>Ability to perform the therapeutic sequence as described in the CIP</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>STEMI - ST Elevation Myocardial Infarction</condition>
  <condition>Microvascular Obstruction</condition>
  <arm_group>
    <arm_group_label>STEMI patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult subjects presenting with STEMI in the LAD undergoing PPCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CorFlow Controlled Flow Infusion System - CoFI™</intervention_name>
    <description>The CorFlow CoFI™ System is intended to assess the dynamic microvascular resistance and to treat microvascular obstruction in the coronary vasculature of patients following PCI with stent placement.</description>
    <arm_group_label>STEMI patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:&#xD;
&#xD;
          -  Patients 18 years of age or older presenting with ST-elevation myocardial infarction&#xD;
             in the left anterior descending artery (LAD) undergoing primary percutaneous coronary&#xD;
             intervention.&#xD;
&#xD;
          -  Competent mental condition to provide signed and dated ethics committee approved study&#xD;
             consent prior to study related procedures&#xD;
&#xD;
          -  Eligible for prasugrel, ticagrelor, cangrelor, tirofiban, UFH and GP IIb/IIIa&#xD;
             inhibitors&#xD;
&#xD;
          -  Referred for primary PCI within 5 hours of symptom onset with evidence of continuing&#xD;
             ischemia and symptom to balloon time not exceeding 6 hours&#xD;
&#xD;
        Major Exclusion Criteria:&#xD;
&#xD;
          -  Unconsciousness&#xD;
&#xD;
          -  Previous bypass graft surgery&#xD;
&#xD;
          -  Contraindication to CMRI&#xD;
&#xD;
          -  Recent or current major bleeding within 30 days prior to intervention&#xD;
&#xD;
          -  Recent major surgery within 30 days prior to intervention&#xD;
&#xD;
          -  End-stage heart failure with inotrope support and/or consideration for LVAD or heart&#xD;
             transplant&#xD;
&#xD;
          -  Transient ischemic attack or stroke within 30 days prior to intervention&#xD;
&#xD;
          -  Pregnant or females of childbearing potential&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanna Catalano</last_name>
    <role>Study Director</role>
    <affiliation>CorFlow Therapeutics AG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giovanna Catalano</last_name>
    <phone>+41 79 690 69 20</phone>
    <email>gcatalano@corflow-therapeutics.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiocentro Ticino</name>
      <address>
        <city>Lugano</city>
        <state>TI</state>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Moccetti, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Marco Moccetti, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Valgimigli, Prof. Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Marco Valgimigli, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HUG Geneva</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan F. Iglesias, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Juan F. Iglesias, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUV Lausanne</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephane Fournier, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Stephane Fournier, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

